Country needs culture of drug reaction assessment for patients’ safety

KARACHI: Adverse drugs reaction is a fact that is direly needed to be taken into account by the local pharmaceutical companies, pharmacologists as well as doctors prescribing medication to the patients.

Experts addressing the certificate distribution ceremony for participants of a course on compilation of adverse drug reaction reports through application of electronic data base “PhVnet,” at Dow Pharmacovigilance (PhV) Centre, Dow University of Health Sciences
sought promotion of a culture of careful and cautious administration of drugs.

“Medicines and drugs are meant to benefit people suffering from ailment yet care is needed to ensure to conduct tolerance tests of the patients administered with the life saving interventions,” said Prof Dr Sumbul Shamim, Head DPhVC and Dean Faculty of Pharmaceutical Sciences, DUHS.

She also referred to progress and achievements registered at Dow PhV Centre (DPhVC) established in July 2013 through joint efforts of DUHS and Dimension Research.

Dr Ismat Ara Khursheed, Director, TB Control Programme for Sindh and Dr Aman ullah Ansari, Technical Officer for the programme in the province referred to implications of medication that may not be monitored or ensured to be administered in accordance to set time table and time line.

DUHS Vice Chancellor, Prof Dr Masood Hameed Khan congratulated the PhV team for achieving the new milestone of being first to assess impact and reaction of drug on most modern lines in local context.

Guest of Honour, Senator Abdul Haseeb Khan, recognized the efforts of Dow University of Health Sciences for establishing the first Pharmacovigilance Centre of the country.

CEO Dimension Research, Khurram Zaki Khan, Zahid Saeed (Managing Director Indus Pharma), Dr Raeef uddin Ahmed (Medical Director, Abbot Labs. Pak Ltd), Sultan Ghani (Pharmaceutical Consultant at Getz Pharma (Pvt ) Ltd), Ahson Awan, Senior Vice Chairman, PPMA also shared their views on the occasion.

The event was attended by representatives of different multi- national companies (MNC), local pharmaceutical companies alongwith management of different hospitals and health care professionals.